ReviewInternational journal of molecular sciences2020
The Potential of Metabolomics in the Diagnosis of Thyroid Cancer.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Lipidomic Profiling: A Promising New Direction in the Diagnosis and Management of Thyroid Cancer?Cureus · 2025Review
- Review
- The causal relationships between inflammatory cytokines, blood metabolites, and thyroid cancer: a two-step Mendelian randomization analysis.Discover oncology · 2025Article
- Analysis of Tryptophan Metabolic Profile Characteristics and Clinical Value in Differentiated Thyroid Cancer Patients.Cancer medicine · 2025Article
- Discrimination of superficial lymph nodes using ultrasonography and tissue metabolomics coupled with machine learning.Frontiers in oncology · 2025Article
- Diagnostics and Therapy for Malignant Tumors.Biomedicines · 2024Review
- In Search of Relevant Urinary Biomarkers for Thyroid Papillary Carcinoma and Benign Thyroid Nodule Differentiation, Targeting Metabolic Profiles and Pathways via UHPLC-QTOF-ESIDiagnostics (Basel, Switzerland) · 2024Article
- TET1 is a Diagnostic and Prognostic Biomarker Associated with Immune Infiltration in Papillary Thyroid Cancer.Biochemical genetics · 2024Article
- Metabolic Profiles and Blood Biomarkers to Discriminate between Benign Thyroid Nodules and Papillary Carcinoma, Based on UHPLC-QTOF-ESIInternational journal of molecular sciences · 2024Article
- Combined metabolomic and lipidomic analysis uncovers metabolic profile and biomarkers for papillary thyroid carcinoma.Scientific reports · 2023Article
- Experimental study on changes in metabolic mechanism of papillary thyroid carcinoma complicated with Hashimoto's thyroiditis.Heliyon · 2023Article
- Article
- Alterations in the amino acid profile in patients with papillary thyroid carcinoma with and without Hashimoto's thyroiditis.Frontiers in endocrinology · 2023Article
- Reprogramming of Cellular Metabolism and Its Therapeutic Applications in Thyroid Cancer.Metabolites · 2022Review
- Integrated microbiome, metabolome, and proteome analysis identifies a novel interplay among commensal bacteria, metabolites and candidate targets in non-small cell lung cancer.Clinical and translational medicine · 2022Article
- An immune-related prognostic signature for thyroid carcinoma to predict survival and response to immune checkpoint inhibitors.Cancer immunology, immunotherapy : CII · 2022Article
- Thyroid Cancer Diagnostics Related to Occupational and Environmental Risk Factors: An Integrated Risk Assessment Approach.Diagnostics (Basel, Switzerland) · 2022Review
- Metabolic Profile Characterization of Different Thyroid Nodules Using FTIR Spectroscopy: A Review.Metabolites · 2022Review
- Key molecules associated with thyroid carcinoma prognosis: A study based on transcriptome sequencing and GEO datasets.Frontiers in immunology · 2022Article
- Applications of spatially resolved omics in the field of endocrine tumors.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
Thyroid cancer is the most common endocrine system malignancy. However, there is still a lack of reliable and specific markers for the detection and staging of this disease. Fine needle aspiration biopsy is the current gold standard for diagnosis of thyroid cancer, but drawbacks to this technique include indeterminate results or an inability to discriminate different carcinomas, thereby requiring additional surgical procedures to obtain a final diagnosis. It is, therefore, necessary to seek more reliable markers to complement and improve current methods. "Omics" approaches have gained much attention in the last decade in the field of biomarker discovery for diagnostic and prognostic characterisation of various pathophysiological conditions. Metabolomics, in particular, has the potential to identify molecular markers of thyroid cancer and identify novel metabolic profiles of the disease, which can, in turn, help in the classification of pathological conditions and lead to a more personalised therapy, assisting in the diagnosis and in the prediction of cancer behaviour. This review considers the current results in thyroid cancer biomarker research with a focus on metabolomics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.